Advertisement


Priscilla K. Brastianos, MD, on Genetic Screening of Brain Metastases

2015 European Cancer Congress

Advertisement

Priscilla K. Brastianos, MD, of Massachusetts General Hospital, discusses genomic characterization of brain metastases and paired primary tumors, which could reveal potential therapeutic targets (Abstract 2905).



Related Videos

Global Cancer Care

Mary K. Gospodarowicz, MD, on Challenges in Cancer Control

Mary K. Gospodarowicz, MD, of Princess Margaret Hospital, discusses the work of the Global Task Force on Radiotherapy for Cancer Control and its efforts to improve access to vital radiation treatment worldwide, especially in low- and middle-income countries.

Kidney Cancer

Robert J. Motzer, MD, on Phase III Results of CheckMate 025 Nivolumab vs Everolimus in Advanced RCC

Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses the results of this study, which could well change the treatment paradigm in patients with previously treated metastatic renal cell carcinoma (Abstract 3LBA).

Kidney Cancer

Toni K. Choueiri, MD, on Cabozantinib vs Everolimus in Patients With Advanced Renal Cell Carcinoma

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozantinib compared to everolimus in patients with disease progression after VEGFR-targeted therapy (Abstract 4LBA).

Kidney Cancer

Brian I. Rini, MD, on A Cancer Vaccine for Renal Cell Carcinoma

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma (Abstract 17LBA).

Gastroesophageal Cancer
Colorectal Cancer
Survivorship

Martine Frouws, MSc, PhD, on Postdiagnosis Aspirin and Improved Survival in All GI Cancers

Martine Frouws, MD, PhD Candidate, of Leiden University Medical Centre discusses her study, which showed a significant increase in overall survival among patients with GI cancers who took aspirin compared to those who did not (Abstract 2306).

Advertisement

Advertisement



Advertisement